Moderna and Merck’s mRNA-4157/V940 + Keytruda Receives PRIME Scheme Designation by the EMA for Adjuvant Treatment of High-Risk Stage III/IV Melanoma
- The PRIME scheme designation was granted based on the results from the P-IIb clinical trial (KEYNOTE-942) evaluating mRNA-4157/V940 + Keytruda vs Keytruda alone in patients (n=157) with stage III/IV melanoma following complete resection. The 1EPs of the study were RFS & 2EPs were distant metastasis-free survival & safety
- The results from the study depicted statistically significant & clinically meaningful improvement in the 1EPs of RFS alone and reduced the risk of recurrence or death by 44% in mRNA-4157/V940 + Keytruda vs Keytruda
- mRNA-4157/V940 is a single synthetic mRNA that can encode for up to 34 neoantigens. It is an mRNA-based personalised cancer vaccine that was created based on the distinct mutational signature of the patient's tumour
Ref: Merck | Image: Moderna
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.